Clinical Efficacy of Dienogest and Levonorgestrel-Releasing Intrauterine System in the Treatment of Adenomyosis

Yang Xu, Li Li, Guixia Yang
In: Journal of Clinical and Nursing Research · 2022 · vol. 6(5) , pp. 139–143 · doi:10.26689/jcnr.v6i5.4213 · W4298144797
article OA: bronze CC0 ⤵ 3 in-corpus citations
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study found the levonorgestrel-releasing intrauterine system (LNG-IUS) had a better therapeutic effect and fewer adverse reactions in treating adenomyosis compared to dienogest (DNG).

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-08 · read from full text ⓘ

This single-center randomized study enrolled 60 patients with adenomyosis (Jan 2020–Oct 2021) and compared dienogest (n=30) versus a levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena; n=30) over 6 months, assessing uterine volume, hemoglobin, pain by VAS, and serum CA125, along with adverse reactions. After treatment, uterine volume changed slightly in both groups without significant differences, while hemoglobin increased in both groups, with a significant improvement reported for the LNG-IUS group but not for dienogest. VAS scores and serum CA125 decreased significantly in both groups. The authors conclude that LNG-IUS had better therapeutic effects and fewer adverse reactions than dienogest, without detailing any other limitations such as sample size beyond the enrolled cohort. This paper is centrally about adenomyosis—comparing dienogest versus levonorgestrel-releasing intrauterine system efficacy and adverse reactions.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Objective: To compare the clinical efficacy and adverse reactions of dienogest and levonorgestrel-releasing intrauterine system in the treatment of adenomyosis. Methods: A total of 60 cases of adenomyosis admitted to Dezhou Women and Children’s Hospital from January 2020 to October 2021 were selected and randomly divided into two groups (Group A and Group B), which were initiated on dienogest and levonorgestrel-releasing intrauterine system, respectively. The therapeutic effects and adverse reactions of the two groups were analyzed. Results: After 6 months of treatment, the uterine volume in the LNG-IUS group reduced slightly compared with that before treatment, with no statistical significance (p > 0.05), while that in the DNG group increased slightly compared with that before treatment, with no statistical significance (p > 0.05). After 6 months of treatment, the hemoglobin of patients in both groups increased compared with that before treatment; there was no significant difference in the DNG group (p > 0.05), but there was significant difference in the LNG-IUS group (p < 0.01). After 6 months of treatment, the VAS scores of the two groups were significantly lower than those before treatment (p < 0.01); the serum CA125 level in both groups decreased significantly compared with that before treatment (p < 0.01). Conclusion: Mirena (levonorgestrel-releasing intrauterine system) has better therapeutic effect on adenomyosis and fewer adverse reactions than deinogest.
Full text 4,277 characters · extracted from oa-doi-fallback · click to expand
Clinical Efficacy of Dienogest and Levonorgestrel-Releasing Intrauterine System in the Treatment of Adenomyosis Objective: To compare the clinical efficacy and adverse reactions of dienogest and levonorgestrel-releasing intrauterine system in the treatment of adenomyosis. Methods: A total of 60 cases of adenomyosis admitted to Dezhou Women and Children’s Hospital from January 2020 to October 2021 were selected and randomly divided into two groups (Group A and Group B), which were initiated on dienogest and levonorgestrel-releasing intrauterine system, respectively. The therapeutic effects and adverse reactions of the two groups were analyzed. Results: After 6 months of treatment, the uterine volume in the LNG-IUS group reduced slightly compared with that before treatment, with no statistical significance (p > 0.05), while that in the DNG group increased slightly compared with that before treatment, with no statistical significance (p > 0.05). After 6 months of treatment, the hemoglobin of patients in both groups increased compared with that before treatment; there was no significant difference in the DNG group (p > 0.05), but there was significant difference in the LNG-IUS group (p < 0.01). After 6 months of treatment, the VAS scores of the two groups were significantly lower than those before treatment (p < 0.01); the serum CA125 level in both groups decreased significantly compared with that before treatment (p < 0.01). Conclusion: Mirena (levonorgestrel-releasing intrauterine system) has better therapeutic effect on adenomyosis and fewer adverse reactions than deinogest. Endometriosis Professional Committee of Gynecologist and Obstetrician Branch of Chinese Medical Doctor Association, 2020, Diagnosis and Treatment of Adenomyosis in China. Chinese Journal of Obstetrics and Gynecology, 55(06): 376–383. Xu K, Lu C, Yang Y, et al., 2021, Progress in the Treatment of Adenomyosis. Journal of Mudanjiang Medical College, 42(03): 132–134. Wang J, He W, Zhou X, et al., 2022, Comparison of Clinical Effects of Dinoprogen and Leuproline in the Adjuvant Treatment of Ovarian Endometriosis Cyst. Chinese Journal of Obstetrics and Gynecology, 23(03): 275–277. Zheng Y, Yi X, Xu C, 2020, Research Progress on the Application of Dinogestrin in the Treatment of Endometriosis. Chinese Journal of Reproduction and Contraception, 40(10): 828–831. Tao G, 2021, Research Progress of Clinical Application of Dinogestrin. China Prescription Drugs, 19(09): 28–29. Yang X, Liu Z, Li H, et al., 2021, Meta Analysis of GnRH-a Combined with Levonorgestrel Intrauterine Sustained Release System in the Treatment of Adenomyosis. China Medical Herald, 18(02): 73–77. Ren L, He S, Chen H, 2022, Clinical Effect of Manyuele on Adenomyosis. China Maternal and Child Health Care, 37(02): 278–281. Matsushima T, Akira S, Fukami T, et al., 2018, Efficacy of Hormonal Therapies for Decreasing Uterine Volume in Patients with Adenomyosis. Gynecol Minim Invasive Ther, 7(3): 119–123. Wang Q, Fu X, Zhu J, 2022, Efficacy Analysis and Safety Evaluation of Dinogestrin in the Treatment of Adenomyosis. Chinese Journal of Practical Gynecology and Obstetrics, 38(01): 105–107. Hirata T, Izumi G, Takamura M, et al., 2014, Efficacy of Dienogest in the Treatment of Symptomatic Adenomyosis: A Pilot Study. Gynecol Endocrinol, 30(10): 726–729. Guo X, Zhu H, 2021, Effect of Leuproline Combined with LNG-IUS in the Treatment of Adenomyosis. Clinical Practice of Integrated Traditional Chinese and Western Medicine, 21(17): 38–40. Zeng W, 2020, Clinical Efficacy of Levonorgestrel Intrauterine Device in the Treatment of Adenomyosis. Electronic Journal of Practical Gynecological Endocrinology, 7(17): 41–42. Takeuchi A, Koga K, Miyashita M, et al., 2016, Dienogest Reduces Proliferation, NGF Expression and Nerve Fiber Density in Human Adenomyosis. Eur J Obstet Gynecol Reprod Biol, 207: 157–161. Osuga Y, Watanabe M, Hagino A, 2017, Long-Term Use of Dienogest in the Treatment of Painful Symptoms in Adenomyosis. The Journal of Obstetrics and Gynaecology Research, 43(9): 1441–1448. Qu J, Mai X, Hu D, et al., 2021, A Clinical Comparative Study on the Treatment of Adenomyosis with Intrauterine Contraceptive System of Dinoprogen and Levonorgestrel. Sino Foreign Medical, 40(29): 117–120.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

Cited by (3)

References (5)

Cited by (3)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK